ROMA Risk of Ovarian Malignancy Algorithm - Serum
Also Known As
Test Parameters Included
- ROMA Risk Score (%) - algorithm combining CA-125 and HE4 with menopausal status
- Pathologist Gynecologic Oncology Remark - risk stratification for epithelial ovarian malignancy
Department
Methodology
Sample Required
Preparation
Schedule Report
24 Hours
Emergency Report
Yes
Frequently Asked Questions
What does the ROMA test measure?
ROMA combines serum CA-125 and HE4 levels with menopausal status to calculate a risk score for epithelial ovarian cancer in women presenting with a pelvic mass.
Is fasting required for ROMA?
No, fasting is not required. The test can be performed on a non-fasting serum sample.
How is the ROMA result interpreted?
Results are given as a percentage risk. Postmenopausal women with ROMA ≥29.9% and premenopausal women with ROMA ≥17.4% are considered high risk and may need referral to a gynecologic oncologist.
What is HE4 and why is it included?
HE4 (Human Epididymis Protein 4) is a tumor marker that is more specific to ovarian cancer than CA-125 alone. Combining both markers improves diagnostic accuracy for detecting ovarian malignancy.
Who should undergo ROMA testing?
ROMA is recommended for women with a known or suspected pelvic mass to help differentiate between benign and malignant ovarian tumors before surgical intervention.
How to access the report?
Verified PDF report is available within 24–48 hours via www.drpatholab.in or WhatsApp/Email.
Test Description
Test Code
R19
- High-end laboratory & medical equipment.
- Outstanding doctor team.
- Personalized care & high-quality service.
- Tailormade health screening packages.